Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?
- PMID: 28741837
- DOI: 10.1111/hiv.12536
Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?
Abstract
Objectives: The aim of the study was to evaluate differences in immunovirological response to combination antiretroviral therapy (cART) in migrant and native men and women within a European collaboration of HIV cohorts Collaboration of Observational HIV Epidemiological Research in Europ (COHERE) in EuroCoord, 2004-2013.
Methods: Migrants were defined as those with geographical origin (GO) different from the reporting country and were grouped as originating from Western Europe and Western Countries (WEWC), Eastern Europe (EE), North Africa and the Middle East (NAME), sub-Saharan Africa (SSA), Latin America (LA), Caribbean (CRB) and Asia/Oceania (ASIA/OCE). Native (NAT) individuals were defined as those originating from the reporting country. CD4 cell counts were modelled using piecewise linear mixed-effects models with two slopes, whereas models to estimate subdistribution hazard ratios (sHRs) were used for time to virological response (VR) (i.e. time from cART initiation to the first of two successive HIV RNA measurements < 400 HIV-1 RNA copies/ml).
Results: Of 32 817 individuals, 25 799 (78.6%) were men. The percentage of migrants was higher in women (48.9%) than in men (21.2%) and migrants from SSA accounted for the largest migrant group (29.9% in men and 63.3% in women). Migrant men and women from SSA started at lower CD4 cell counts than NAT individuals, which remained lower over time. VR was ≥ 85% at 12 months for all groups except CRB women (77.7%). Compared with NAT men and women, lower VR was experienced by NAME [sHR 0.91; 95% confidence interval (CI) 0.86-0.97] and SSA (sHR 0.88; 95% CI 0.82-0.95) men and CRB (sHR 0.77; 85% CI 0.67-0.89) women, respectively.
Conclusions: Immunovirological response to cART in Western Europe varies by GO and sex of patients. ART benefits are not equal for all, underlining the point that efforts need to prioritize those most in need.
Keywords: HIV; combination antiretroviral therapy; immunovirological response; migrants; sex.
© 2017 British HIV Association.
Similar articles
-
Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe.AIDS. 2017 Mar 27;31(6):835-846. doi: 10.1097/QAD.0000000000001411. AIDS. 2017. PMID: 28272136
-
Does region of origin influence the timing and outcome of first-line antiretroviral therapy in France?HIV Med. 2019 Feb;20(2):175-181. doi: 10.1111/hiv.12697. Epub 2018 Dec 3. HIV Med. 2019. PMID: 30506853
-
Mortality in migrants living with HIV in western Europe (1997-2013): a collaborative cohort study.Lancet HIV. 2015 Dec;2(12):e540-9. doi: 10.1016/S2352-3018(15)00203-9. Epub 2015 Nov 18. Lancet HIV. 2015. PMID: 26614968
-
CD4-cell counts and presence of AIDS in HIV-positive patients entering specialized care-a comparison of migrant groups in the German ClinSurv HIV Cohort Study, 1999-2013.BMC Infect Dis. 2016 Dec 7;16(1):739. doi: 10.1186/s12879-016-2070-5. BMC Infect Dis. 2016. PMID: 27927190 Free PMC article.
-
Later cART initiation in migrant men from sub-Saharan Africa without advanced HIV disease in France.PLoS One. 2015 Mar 3;10(3):e0118492. doi: 10.1371/journal.pone.0118492. eCollection 2015. PLoS One. 2015. PMID: 25734445 Free PMC article.
Cited by
-
Promoting HIV, Hepatitis B Virus, and Hepatitis C Virus Screening Among Migrants With a Language Barrier: Protocol for the Development and Evaluation of an Electronic App (Apidé).JMIR Res Protoc. 2021 May 5;10(5):e22239. doi: 10.2196/22239. JMIR Res Protoc. 2021. PMID: 33949963 Free PMC article.
-
Viral rebound on antiretroviral therapy in France according to region of origin, sex, and HIV acquisition group. Results from the French Hospital Database on HIV (ANRS CO4-FHDH).HIV Med. 2025 Feb;26(2):252-264. doi: 10.1111/hiv.13729. Epub 2024 Nov 4. HIV Med. 2025. PMID: 39497481 Free PMC article.
-
Respective roles of migration and social deprivation for virological non-suppression in HIV-infected adults on antiretroviral therapy in France.PLoS One. 2019 Mar 7;14(3):e0213019. doi: 10.1371/journal.pone.0213019. eCollection 2019. PLoS One. 2019. PMID: 30845270 Free PMC article.
-
Longitudinal virological outcomes and factors associated with virological failure in behaviorally HIV-infected young adults on combination antiretroviral treatment in the Netherlands, 2000 to 2015.Medicine (Baltimore). 2019 Aug;98(32):e16357. doi: 10.1097/MD.0000000000016357. Medicine (Baltimore). 2019. PMID: 31393344 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials